Hypoxia-inducible factor 2-alpha–Tat-interactive protein 30 axis (HIF-2α–TIP30 axis)

The Hypoxia-inducible factor 2-alpha–Tat-interactive protein 30 (HIF-2α–TIP30) axis is a critical regulatory pathway involved in the progression of various malignancies, particularly clear cell renal cell carcinoma (ccRCC) and hepatocellular carcinoma [1, 2]. HIF-2α (encoded by EPAS1) is a transcription factor that is frequently overactivated in tumors with Von Hippel-Lindau (VHL) mutations, leading to the expression of genes that promote angiogenesis and cell survival [1, 3]. TIP30 (encoded by HTATIP2) is a tumor suppressor that facilitates the endocytic degradation of growth factor receptors like EGFR and induces apoptosis [2, 4]. Within this axis, stabilized HIF-2α acts to suppress the expression of TIP30, which results in sustained oncogenic signaling and increased metastatic potential [2, 5]. Therapeutic targeting of this axis primarily involves the use of small-molecule HIF-2α inhibitors, such as Belzutifan, which prevent the assembly of the HIF-2α/HIF-1β transcriptional complex [3, 6]. By blocking HIF-2α activity, these agents can restore TIP30 levels, thereby inhibiting the downstream proliferative signals that drive tumor growth [2, 6]. This axis is a significant focus of research for overcoming resistance to conventional therapies and providing targeted options for patients with VHL-related cancers [3, 5].

Other names

EPAS1-HTATIP2 axisHIF2A-TIP30 pathwayHIF-2α-HTATIP2 signaling axisHIF-2α-regulated TIP30 signaling

Small molecule inhibition of HIF-2α prevents its dimerization with HIF-1β (ARNT), thereby blocking the transcriptional program that suppresses TIP30 and drives tumor progression.